前列地尔脂微球注射液治疗进展性脑梗死的疗效观察

目的:观察前列地尔脂微球注射液治疗进展性脑梗死的临床效果。方法:将2010年1月-2011年1月我院收治的进展性脑梗死患者120例,随机均分为试验组与对照组:对照组采用丹参注射液20 mL.d-1治疗,试验组在对照组基础上加用前列地尔脂微球注射液10μg.d-1治疗。观察2组疗效及不良反应。结果:试验组患者临床疗效总有效率为85.00%,对照组为66.67%,2组比较差异有统计学意义(P<0.05);治疗前、后2组患者的NIHSS评分及Barthel评分组内比较差异均具有统计学意义(P<0.05),且治疗30d后试验组患者的NIHSS评分显著低于对照组(P<0.05),Barthel评分显著高于对照组(P<0.05);2组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论:前列地尔脂微球注射液治疗进展性脑梗死疗效较好、不良反应较小。

Efficacy Observation of Lipo-alprostadil Injection in the Treatment of Progressive Cerebral Infarction

OBJECTIVE： To investigate the application of Lipo-alprostadil injection in the treatment of progressive cerebral in- farction. METHODS： 120 patients with progressive cerebral infarction in our hospital during Jan. 2010--Jan. 2011 were randomly divided into experiment group and control group. Control group was given Danshen injection（20 mL.d-1）, and experiment group was additionally given Lipo-alprostadil injection（10μg· d-1） on the basis of the treatment for control group. The efficacy and ADRs were observed in 2 groups. RESULTS： Total effective rate of experiment group was 85.00% and that of control group was only 66.67%, which indicated clinical efficacy of experiment group was better than that of control group （P〈0.05） ; there was statisti- cal significance in the difference of NIHSS score and Barthel score between 2 groups before and after treatment （P〈0.05） ; after 30 days of treatment, NHSS score of experiment group was significantly lower than that of control group （P〈0.05）, while Barthel score was higher than control group （P〈0.05）; there was no statistical significance in the difference of the incidence of ADR between 2 groups （P〉0.05）. CONCLUSION： Lipo-alprostadil injection is safe and reliable in the treatment of progressive cerebral in- farction with sound efficacy and little ADR.